Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Healthcare Triangle, Inc.HCTI · Entity 7909 | Director | August 19, 2022 | August 22, 2022 |
| MetaVia Inc.GEMP · Entity 7947 | Chief Financial Officer | January 28, 2018 | January 30, 2018 |
| NEUROONE MEDICAL TECHNOLOGIES CorpNMTC · Entity 7808 | Director | April 03, 2026 | April 07, 2026 |
| Panbela Therapeutics, Inc.PBLA · Entity 11460 | Director | March 27, 2023 | March 29, 2023 |
| Solana CoHSDT · Entity 6630 | Director · CFO and Treasurer | July 02, 2025 | July 04, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Healthcare Triangle, Inc.
Report date August 19, 2022 · Filed August 22, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.63 · Expires 2023-03-30 | Direct | 20,000 |
Reported balance
Holding disclosure · report date 2022-08-19 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance 20,000 F1: This Option will become exercisable ("vest") on March 30, 2023. With respect to vested Shares Subject to Option, this Option shall expire on the earlier of (x) November 29, 2026 and (y) 18 months after the date of Termination, and not be exercisable for any Shares. |
Filing footnotes · ownership attribution and instrument terms
F1: This Option will become exercisable ("vest") on March 30, 2023. With respect to vested Shares Subject to Option, this Option shall expire on the earlier of (x) November 29, 2026 and (y) 18 months after the date of Termination, and not be exercisable for any Shares.
MetaVia Inc.
Report date January 28, 2018 · Filed January 30, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.10 · Expires 2028-01-27 | Direct | 48,000 |
Reported balance
After 2018-01-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-01-28 · Grant · Acquired 48,000 · Balance 48,000 F1: The option vests in a series of 48 successive equal monthly installments on the last day of each month, commencing on the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in a series of 48 successive equal monthly installments on the last day of each month, commencing on the grant date.
NEUROONE MEDICAL TECHNOLOGIES Corp
Report date April 03, 2026 · Filed April 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 156,343 |
Reported balance
After 2026-04-03 transaction · row 1
1 source rowRow 1 · 2026-04-03 · Grant · Acquired 41,929 · Balance 156,343 F1: Represents a grant of restricted stock units, which vest in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.80 · Expires 2036-04-02 | Direct | 26,036 |
Reported balance
After 2026-04-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-03 · Grant · Acquired 26,036 · Balance 26,036 F2: The option vests in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units, which vest in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month.
F2: The option vests in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month.
Panbela Therapeutics, Inc.
Report date March 27, 2023 · Filed March 29, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2033-03-27 | Direct | 8,333 |
Reported balance
After 2023-03-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-27 · Grant · Acquired 8,333 · Balance 8,333 F1: Options scheduled to vest on the earlier of day before annual meeting of stockholders or one year anniversary. |
Filing footnotes · ownership attribution and instrument terms
F1: Options scheduled to vest on the earlier of day before annual meeting of stockholders or one year anniversary.
Solana Co
Report date July 02, 2025 · Filed July 04, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.76 · Expires 2035-07-01 | Direct | 26,200 |
Reported balance
After 2025-07-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-07-02 · Grant · Acquired 26,200 · Balance 26,200 F1: Grant to the Reporting Person of a stock option under the Issuer's 2022 Equity Incentive Plan. 50% of the options vested immediately upon grant, and the remaining options vest in a series of twelve (12) successive equal quarterly installments on the last day of each quarter starting on September 30, 2025, subject to the Reporting Person's continued service through each applicable vesting period. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant to the Reporting Person of a stock option under the Issuer's 2022 Equity Incentive Plan. 50% of the options vested immediately upon grant, and the remaining options vest in a series of twelve (12) successive equal quarterly installments on the last day of each quarter starting on September 30, 2025, subject to the Reporting Person's continued service through each applicable vesting period.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 03, 2026 Filed Apr 7, 2026 17:38 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantOption to Purchase Common Stock · Derivative | 26,036 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001296853-26-000001 · primary_doc.xml · derivative · entry 2 MATHIESEN JEFFREY S · CIK 0001296853 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,036 Underlying: Common Stock · 26,036 shares Expires 2036-04-02 F2 · derivative.exercise_date: The option vests in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month. Read SEC document |
| April 03, 2026 Filed Apr 7, 2026 17:38 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantCommon Stock | 41,929 | $0.00 | $0.00 |
DisclosureSEC source: 0001296853-26-000001 · primary_doc.xml · nonDerivative · entry 1 MATHIESEN JEFFREY S · CIK 0001296853 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,343 F1 · shares: Represents a grant of restricted stock units, which vest in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month. Read SEC document |
| July 02, 2025 Filed Jul 4, 2025 00:00 UTC | Solana Co HSDT · Entity 6630 | GrantStock Option (Right to Buy) · Derivative | 26,200 | $0.00 Strike: $9.76 | $0.00 |
DisclosureSEC source: 0001140361-25-024937 · form4.xml · derivative · entry 1 MATHIESEN JEFFREY S · CIK 0001296853 · Director · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,200 Underlying: Class A Common Stock · 26,200 shares Expires 2035-07-01 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2022 Equity Incentive Plan. 50% of the options vested immediately upon grant, and the remaining options vest in a series of twelve (12) successive equal quarterly installments on the last day of each quarter starting on September 30, 2025, subject to the Reporting Person's continued service through each applicable vesting period. Read SEC document |
| June 23, 2025 Filed Jun 25, 2025 19:47 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantOption to Purchase Common Stock · Derivative | 50,000 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0001656026-25-000004 · primary_doc.xml · derivative · entry 1 MATHIESEN JEFFREY S · CIK 0001296853 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-06-23 F1 · derivative.exercise_date: The option vests in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 17:00 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantOption to Purchase Common Stock · Derivative | 17,025 | $0.00 Strike: $1.20 | $0.00 |
DisclosureSEC source: 0001213900-25-015155 · ownership.xml · derivative · entry 2 MATHIESEN JEFFREY S · CIK 0001296853 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,025 Underlying: Common Stock · 17,025 shares Expires 2035-02-14 F2 · derivative.exercise_date: The option vests in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 17:00 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantCommon Stock | 27,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-015155 · ownership.xml · nonDerivative · entry 1 MATHIESEN JEFFREY S · CIK 0001296853 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,414 F1 · shares: Represents a grant of restricted stock units, which vest in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month. Read SEC document |
| January 06, 2025 Filed Jan 8, 2025 21:10 UTC | Solana Co HSDT · Entity 6630 | GrantStock Option (Right to Buy) · Derivative | 139,857 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001140361-25-000618 · form4.xml · derivative · entry 1 MATHIESEN JEFFREY S · CIK 0001296853 · Director · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,857 Underlying: Class A Common Stock · 139,857 shares Expires 2035-01-05 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2022 Equity Incentive Plan. 50% of the options vested immediately upon grant, and the remaining options vest in a series of twelve (12) successive equal quarterly installments on the last day of each quarter starting on March 31, 2025, subject to the Reporting Person's continued service through each applicable vesting period. Read SEC document |
| July 02, 2024 Filed Jul 5, 2024 21:00 UTC | Solana Co HSDT · Entity 6630 | GrantStock Option (Right to Buy) · Derivative | 404,000 | $0.00 Strike: $0.97 | $0.00 |
DisclosureSEC source: 0001140361-24-032525 · form4.xml · derivative · entry 1 MATHIESEN JEFFREY S · CIK 0001296853 · Director · CFO and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 404,000 Underlying: Class A Common Stock · 404,000 shares Expires 2034-07-01 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2022 Equity Incentive Plan. 62.5% of the options vested immediately upon grant, and the remaining options vest in a series of ten (10) successive equal quarterly installments on the last day of each quarter starting on September 30, 2024, subject to the Reporting Person's continued service through each applicable vesting period. Read SEC document |
| March 27, 2023 Filed Mar 29, 2023 16:19 UTC | Panbela Therapeutics, Inc. PBLA · Entity 11460 | GrantStock Option (right to buy) · Derivative | 8,333 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001437749-23-008406 · rdgdoc.xml · derivative · entry 1 MATHIESEN JEFFREY S · CIK 0001296853 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,333 Underlying: Common Stock · 8,333 shares Expires 2033-03-27 F1 · derivative.exercise_date: Options scheduled to vest on the earlier of day before annual meeting of stockholders or one year anniversary. Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 18:06 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantOption to Purchase Common Stock · Derivative | 18,927 | $0.00 Strike: $1.62 | $0.00 |
DisclosureSEC source: 0001213900-23-021351 · marketforms-60940.xml · derivative · entry 2 MATHIESEN JEFFREY S · CIK 0001296853 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,927 Underlying: Common Stock · 18,927 shares Expires 2033-03-16 F2 · derivative.exercise_date: The option vests in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month. Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 18:06 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantCommon Stock | 20,576 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-23-021351 · marketforms-60940.xml · nonDerivative · entry 1 MATHIESEN JEFFREY S · CIK 0001296853 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,636 F1 · shares: Represents a grant of restricted stock units, which vest in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month. Read SEC document |
| February 14, 2023 Filed Feb 17, 2023 00:12 UTC | Solana Co HSDT · Entity 6630 | GrantStock Option (Right to Buy) · Derivative | 2,693,000 | $0.00 Strike: $0.31 | $0.00 |
DisclosureSEC source: 0001140361-23-007527 · form4.xml · derivative · entry 1 MATHIESEN JEFFREY S · CIK 0001296853 · Director · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,693,000 Underlying: Common Stock · 2,693,000 shares Expires 2033-02-13 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2022 Equity Incentive Plan. The options vest in a series of twelve (12) successive equal quarterly installments on the last day of each quarter so that all of the options will be vested on the three-year anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting period. Read SEC document |
| September 13, 2022 Filed Sep 14, 2022 20:40 UTC | Solana Co HSDT · Entity 6630 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $0.54 | $0.00 |
DisclosureSEC source: 0001104659-22-100055 · tm2225892-1_4seq1.xml · derivative · entry 1 MATHIESEN JEFFREY S · CIK 0001296853 · Director · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2032-09-12 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2022 Equity Incentive Plan. The options vest in a series of twelve (12) successive equal quarterly installments on the last day of each quarter so that all of the options will be vested on the three-year anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting period. Read SEC document |
| May 31, 2022 Filed Jun 2, 2022 20:22 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantOption to Purchase Common Stock · Derivative | 29,230 | $0.00 Strike: $1.14 | $0.00 |
DisclosureSEC source: 0001596771-22-000017 · primary_doc.xml · derivative · entry 2 MATHIESEN JEFFREY S · CIK 0001296853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,230 Underlying: Common Stock · 29,230 shares Expires 2032-05-31 F2 · derivative.exercise_date: The option vests in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month. Read SEC document |
| May 31, 2022 Filed Jun 2, 2022 20:22 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantCommon Stock | 29,240 | $0.00 | $0.00 |
DisclosureSEC source: 0001596771-22-000017 · primary_doc.xml · nonDerivative · entry 1 MATHIESEN JEFFREY S · CIK 0001296853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,060 F1 · shares: Represents a grant of restricted stock units, which vest in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month. Read SEC document |
| May 23, 2022 Filed May 25, 2022 20:31 UTC | Solana Co HSDT · Entity 6630 | GrantStock Option (Right to Buy) · Derivative | 37,000 | $0.00 Strike: $4.68 | $0.00 |
DisclosureSEC source: 0001140361-22-020576 · form4.xml · derivative · entry 1 MATHIESEN JEFFREY S · CIK 0001296853 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,000 Underlying: Common Stock · 37,000 shares Expires 2032-05-22 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option to purchase 37,000 shares of common stock under the Issuer's 2022 Equity Incentive Plan. Vests as to 6,170 shares on June 30, 2022, with the remainder vesting in 10 equal amounts on the last day of each fiscal quarter thereafter. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 21:10 UTC | Solana Co HSDT · Entity 6630 | GrantClass A Common Stock | 8,011 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-011221 · doc4.xml · nonDerivative · entry 1 MATHIESEN JEFFREY S · CIK 0001296853 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,948 F1 · shares: Grant to the Reporting Person of a stock award under the Issuer's 2018 Omnibus Incentive Plan. Read SEC document |
| December 17, 2021 Filed Dec 20, 2021 13:15 UTC | Solana Co HSDT · Entity 6630 | PurchaseClass A Common Stock | 3,000 | $5.31 | $15,929.40 |
DisclosureSEC source: 0001209191-21-070472 · doc4.xml · nonDerivative · entry 1 MATHIESEN JEFFREY S · CIK 0001296853 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,937 F1 · price: The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.24 to $5.37 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 14, 2021 Filed Jun 15, 2021 20:05 UTC | Solana Co HSDT · Entity 6630 | GrantStock Option (Right to Buy) · Derivative | 77,250 | $0.00 Strike: $15.57 | $0.00 |
DisclosureSEC source: 0001209191-21-040556 · doc4.xml · derivative · entry 1 MATHIESEN JEFFREY S · CIK 0001296853 · CFO and Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,250 Underlying: Common Stock · 77,250 shares Expires 2031-06-13 F1 · derivative.exercise_date: Grant to the Reporting Person of a stock option to purchase 103,000 shares of common stock under the Issuer's 2018 Omnibus Incentive Plan. 25% of the shares are fully vested as of the grant date; 25% of the shares granted, which will be reported when earned, will vest based on a performance condition; of the remaining shares, 25% of such number remaining shall vest on the one year anniversary of the grant date, and the remainder shall vest in thirty-six successive equal monthly installments on the last day of each full month, subject to the Reporting Person's continuous service through each applicable vesting period. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 20:29 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantOption to Purchase Common Stock · Derivative | 4,682 | $0.00 Strike: $7.26 | $0.00 |
DisclosureSEC source: 0001596771-21-000039 · primary_doc.xml · derivative · entry 2 MATHIESEN JEFFREY S · CIK 0001296853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,682 Underlying: Common Stock · 4,682 shares Expires 2031-06-02 F3 · derivative.exercise_date: The option vests in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 20:29 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantCommon Stock | 4,592 | $0.00 | $0.00 |
DisclosureSEC source: 0001596771-21-000039 · primary_doc.xml · nonDerivative · entry 1 MATHIESEN JEFFREY S · CIK 0001296853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,811 F1 · shares: Represents a grant of restricted stock units, which vest in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month. F2 · balance_after: The share amount has been adjusted to reflect the reverse stock split effective on March 31, 2021 whereby each three shares issued and outstanding prior to the split were combined and converted into one share of common stock. Read SEC document |
| May 25, 2021 Filed May 27, 2021 20:51 UTC | Panbela Therapeutics, Inc. PBLA · Entity 11460 | GrantStock Option (right to buy) · Derivative | 12,368 | $0.00 Strike: $4.17 | $0.00 |
DisclosureSEC source: 0001437749-21-013593 · rdgdoc.xml · derivative · entry 2 MATHIESEN JEFFREY S · CIK 0001296853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,368 Underlying: Common Stock · 12,368 shares Expires 2031-05-25 F1 · derivative.exercise_date: Scheduled to vest and become exercisable in four equal increments on August 25, 2021, November 24, 2021, February 25, 2022 and the earlier of May 31, 2022 and the day before the company's annual meeting of stockholders to be held in 2022. Read SEC document |
| May 25, 2021 Filed May 27, 2021 20:51 UTC | Panbela Therapeutics, Inc. PBLA · Entity 11460 | GrantCommon Stock | 4,316 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-21-013593 · rdgdoc.xml · nonDerivative · entry 1 MATHIESEN JEFFREY S · CIK 0001296853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,191 Read SEC document |
| May 25, 2021 Filed May 27, 2021 20:11 UTC | Solana Co HSDT · Entity 6630 | GrantStock Option (Right to Buy) · Derivative | 3,063 | $0.00 Strike: $13.30 | $0.00 |
DisclosureSEC source: 0001209191-21-036235 · doc4.xml · derivative · entry 2 MATHIESEN JEFFREY S · CIK 0001296853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,063 Underlying: Class A Common Stock · 3,063 shares Expires 2031-05-24 F2 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2018 Omnibus Incentive Plan. The options vest in a series of twelve (12) successive equal monthly installments on the last day of each month so that all of the options will be vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting period. Read SEC document |
| May 25, 2021 Filed May 27, 2021 20:11 UTC | Solana Co HSDT · Entity 6630 | GrantClass A Common Stock | 937 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-036235 · doc4.xml · nonDerivative · entry 1 MATHIESEN JEFFREY S · CIK 0001296853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 937 F1 · shares: Grant to the Reporting Person of restricted stock units ("RSUs") under the Issuer's 2018 Omnibus Incentive Plan. The RSUs vest in a series of twelve (12) successive equal monthly installments on the last day of each month so that all of the RSUs will be vested on the one-year anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting period. Read SEC document |
| December 01, 2020 Filed Dec 3, 2020 16:13 UTC | Panbela Therapeutics, Inc. PBLA · Entity 11460 | GrantCommon Stock | 2,875 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-20-024771 · rdgdoc.xml · nonDerivative · entry 1 MATHIESEN JEFFREY S · CIK 0001296853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,875 Read SEC document |
| June 24, 2020 Filed Jun 26, 2020 16:49 UTC | Panbela Therapeutics, Inc. SNBP · Entity 11460 | GrantStock Option (right to buy) · Derivative | 13,700 | $0.00 Strike: $4.98 | $0.00 |
DisclosureSEC source: 0001437749-20-014005 · rdgdoc.xml · derivative · entry 1 MATHIESEN JEFFREY S · CIK 0001296853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,700 Underlying: Common Stock · 13,700 shares Expires 2030-06-24 F1 · derivative.exercise_date: Scheduled to become fully exercisable the day before the annual meeting of stockholders to be held in 2021. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 19:12 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | Exercise / conversionOption to Purchase Common Stock · Derivative | 34,020 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001596771-20-000053 · primary_doc.xml · derivative · entry 2 MATHIESEN JEFFREY S · CIK 0001296853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,020 shares Expires 2027-04-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 15, 2020 Filed Jun 17, 2020 19:12 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | Exercise / conversionCommon Stock | 34,020 | $0.04 | $1,190.70 |
DisclosureSEC source: 0001596771-20-000053 · primary_doc.xml · nonDerivative · entry 1 MATHIESEN JEFFREY S · CIK 0001296853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,658 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 21:27 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantOption to Purchase Common Stock · Derivative | 23,725 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001596771-20-000047 · primary_doc.xml · derivative · entry 2 MATHIESEN JEFFREY S · CIK 0001296853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,725 Underlying: Common Stock · 23,725 shares Expires 2030-06-02 F2 · derivative.exercise_date: The option vests in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 21:27 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantCommon Stock | 22,371 | $0.00 | $0.00 |
DisclosureSEC source: 0001596771-20-000047 · primary_doc.xml · nonDerivative · entry 1 MATHIESEN JEFFREY S · CIK 0001296853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,638 F1 · shares: Represents a grant of restricted stock units, which vest in 12 equal monthly installments over a one-year period, with such vesting to occur at the end of each month. Read SEC document |
| February 10, 2020 Filed Feb 11, 2020 21:45 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantCommon Stock | 26,261 | $0.00 | $0.00 |
DisclosureSEC source: 0001596771-20-000003 · primary_doc.xml · nonDerivative · entry 1 MATHIESEN JEFFREY S · CIK 0001296853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,267 F1 · shares: Represents a grant of restricted stock units, which were fully vested on the date of grant. Read SEC document |
| November 05, 2019 Filed Nov 7, 2019 21:22 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantOption to Purchase Common Stock · Derivative | 100,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001596771-19-000133 · primary_doc.xml · derivative · entry 1 MATHIESEN JEFFREY S · CIK 0001296853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-11-05 Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 23:05 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantOption to Purchase Common Stock · Derivative | 14,995 | $0.00 Strike: $2.38 | $0.00 |
DisclosureSEC source: 0001596771-19-000062 · primary_doc.xml · derivative · entry 2 MATHIESEN JEFFREY S · CIK 0001296853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,995 Underlying: Common Stock · 14,995 shares Expires 2029-06-04 F2 · derivative.exercise_date: Vests in 12 approximately equal consecutive monthly increments, commencing on the one-month anniversary of the date of grant, so that all of the options will be vested on the one-year anniversary of the date of grant. Read SEC document |
| June 04, 2019 Filed Jun 6, 2019 23:05 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantCommon Stock | 14,006 | $0.00 | $0.00 |
DisclosureSEC source: 0001596771-19-000062 · primary_doc.xml · nonDerivative · entry 1 MATHIESEN JEFFREY S · CIK 0001296853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,006 F1 · shares: Represents a grant of restricted stock units. Vests in 12 approximately equal consecutive monthly increments, commencing on the one-month anniversary of the date of grant, so that all of the shares will be vested on the one-year anniversary of the date of grant. Read SEC document |
| May 21, 2019 Filed May 23, 2019 19:28 UTC | Panbela Therapeutics, Inc. SNBP · Entity 11460 | GrantStock Option (right to buy) · Derivative | 6,800 | $0.00 Strike: $2.95 | $0.00 |
DisclosureSEC source: 0001437749-19-010782 · rdgdoc.xml · derivative · entry 2 MATHIESEN JEFFREY S · CIK 0001296853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,800 Underlying: Common Stock · 6,800 shares Expires 2029-05-21 F2 · derivative.exercise_date: Immediately exercisable as to 50% of the shares and scheduled to vest with respect to 25% of the shares on each of May 21, 2020 and May 21, 2021. Read SEC document |
| May 21, 2019 Filed May 23, 2019 19:28 UTC | Panbela Therapeutics, Inc. SNBP · Entity 11460 | GrantStock Option (right to buy) · Derivative | 27,000 | $0.00 Strike: $2.95 | $0.00 |
DisclosureSEC source: 0001437749-19-010782 · rdgdoc.xml · derivative · entry 1 MATHIESEN JEFFREY S · CIK 0001296853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2029-05-21 F1 · derivative.exercise_date: Scheduled to become fully exercisable the day before the annual meeting of stockholders to be held in 2020. Read SEC document |
| May 13, 2019 Filed May 15, 2019 20:33 UTC | NEUROONE MEDICAL TECHNOLOGIES Corp NMTC · Entity 7808 | GrantOption to Purchase Common Stock · Derivative | 45,605 | $0.00 Strike: $2.38 | $0.00 |
DisclosureSEC source: 0001596771-19-000044 · primary_doc.xml · derivative · entry 1 MATHIESEN JEFFREY S · CIK 0001296853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,605 Underlying: Common Stock · 45,605 shares Expires 2029-05-13 Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 17:30 UTC | Panbela Therapeutics, Inc. SNBP · Entity 11460 | PurchaseWarrant (right to buy) · Derivative | 3,000 | Not disclosed Strike: $5.00 | Not disclosed |
DisclosureSEC source: 0001437749-18-003129 · rdgdoc.xml · derivative · entry 2 MATHIESEN JEFFREY S · CIK 0001296853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires 2021-02-20 F1 · price: Reported securities purchased as one share of common stock and one warrant to purchase one share of common stock for a combined price of $5.00 per "unit." Read SEC document |
| February 20, 2018 Filed Feb 22, 2018 17:30 UTC | Panbela Therapeutics, Inc. SNBP · Entity 11460 | PurchaseCommon Stock | 3,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-18-003129 · rdgdoc.xml · nonDerivative · entry 1 MATHIESEN JEFFREY S · CIK 0001296853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · price: Reported securities purchased as one share of common stock and one warrant to purchase one share of common stock for a combined price of $5.00 per "unit." Read SEC document |
| January 28, 2018 Filed Jan 30, 2018 21:20 UTC | MetaVia Inc. GEMP · Entity 7947 | GrantEmployee Stock Option (right to buy) · Derivative | 48,000 | $0.00 Strike: $10.10 | $0.00 |
DisclosureSEC source: 0001596771-18-000011 · primary_doc.xml · derivative · entry 1 MATHIESEN JEFFREY S · CIK 0001296853 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,000 Underlying: Common Stock · 48,000 shares Expires 2028-01-27 F1 · derivative.exercise_date: The option vests in a series of 48 successive equal monthly installments on the last day of each month, commencing on the grant date. Read SEC document |
| August 14, 2017 Filed Aug 16, 2017 20:10 UTC | MetaVia Inc. GEMP · Entity 7947 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,207 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001596771-17-000067 · primary_doc.xml · derivative · entry 2 MATHIESEN JEFFREY S · CIK 0001296853 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,207 shares Expires 2025-09-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 14, 2017 Filed Aug 16, 2017 20:10 UTC | MetaVia Inc. GEMP · Entity 7947 | Exercise / conversionCommon Stock | 3,207 | $3.59 | $11,513.13 |
DisclosureSEC source: 0001596771-17-000067 · primary_doc.xml · nonDerivative · entry 1 MATHIESEN JEFFREY S · CIK 0001296853 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,134 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2017 Filed Aug 11, 2017 20:07 UTC | MetaVia Inc. GEMP · Entity 7947 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001104659-17-051365 · a4.xml · derivative · entry 2 MATHIESEN JEFFREY S · CIK 0001296853 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires 2025-09-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2017 Filed Aug 11, 2017 20:07 UTC | MetaVia Inc. GEMP · Entity 7947 | Exercise / conversionCommon Stock | 3,000 | $3.59 | $10,770.00 |
DisclosureSEC source: 0001104659-17-051365 · a4.xml · nonDerivative · entry 1 MATHIESEN JEFFREY S · CIK 0001296853 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,927 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2017 Filed Aug 15, 2017 20:22 UTC Amendment | MetaVia Inc. GEMP · Entity 7947 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0001596771-17-000066 · primary_doc.xml · derivative · entry 2 MATHIESEN JEFFREY S · CIK 0001296853 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,093 Underlying: Common Stock · 3,000 shares Expires 2025-09-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Amended to correct an error related to the number of shares subject to the reported option following the exercise. Read SEC document |
| August 10, 2017 Filed Aug 15, 2017 20:22 UTC Amendment | MetaVia Inc. GEMP · Entity 7947 | Exercise / conversionCommon Stock | 3,000 | $3.59 | $10,770.00 |
DisclosureSEC source: 0001596771-17-000066 · primary_doc.xml · nonDerivative · entry 1 MATHIESEN JEFFREY S · CIK 0001296853 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,927 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 12, 2016 Filed Dec 14, 2016 17:02 UTC | Panbela Therapeutics, Inc. SNBP · Entity 11460 | GrantStock Option (right to buy) · Derivative | 208,000 | $0.00 Strike: $1.51 | $0.00 |
DisclosureSEC source: 0001437749-16-043355 · rdgdoc.xml · derivative · entry 1 MATHIESEN JEFFREY S · CIK 0001296853 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,000 Underlying: Common Stock · 208,000 shares Expires 2026-12-12 F1 · derivative.exercise_date: Options scheduled to vest as to 50% of the shares on December 12, 2016 and as to 25% of the shares on each of June 12, 2017 and December 12, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.